Bioregnum channel feed

As the XBI suf­fers, Q1 shows a few com­fort­ing signs of un­der­ly­ing sta­bil­i­ty

5 days ago

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

4 weeks ago
R&D
Special

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

2 months ago
Financing

A mixed year for deals and dol­lars left biotech ex­ecs hun­gry for a bet­ter 2025

3 months ago
Deals

The End­points 100: The biotech in­dus­try braces for Trump 2.0

4 months ago
Deals
R&D

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

6 months ago
Financing
Startups

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists trig­gered a rev­o­lu­tion

7 months ago
R&D

It’s time to nom­i­nate your fa­vorite pri­vate biotech for this year’s End­points 11

10 months ago

Af­ter 14 years call­ing part­ner­ing shots at Genen­tech/Roche, James Sabry is head­ed back in­to the biotech fray

11 months ago
People

Trail­blaz­ers, icon­o­clasts and break­through artists are com­ing to the End­points biotech sum­mit — please join us

11 months ago

Pas­cal So­ri­ot’s been push­ing for US-sized CEO pay for more than a decade. Now he’s fi­nal­ly get­ting it

Last year
People
Pharma

Big come­back? The Q1 re­port on biotech is in, and there’s been some sput­ter­ing

Last year
Financing
Deals

The R&D 15: Top phar­ma play­ers shell out record $153B for re­search, and M&A is a prime fo­cus for all

Last year
R&D
Special

The top 100 ven­ture play­ers in bio­phar­ma to­day. Who's in? What's out?

Last year
Financing

Law­mak­ers’ ex­plo­sive charges turn a glob­al spot­light on Chi­na’s WuXi, and it’s feel­ing the heat

Last year
China

We just had a string of suc­cess­ful biotech IPOs. Now what?

Last year

Biotech deal­mak­ing shows some signs of a turn­around. And the in­dus­try is keep­ing its fin­gers crossed

Last year

As the biotech fund­ing game changed, TCGX al­tered course — and now they’re back with $1B for round two

Last year
Financing

Head­ed to San Fran­cis­co? Here’s how you can cus­tomize your ex­pe­ri­ence at #JPM24 with End­points News

Last year
R&D

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

Last year

Flag­ship Pi­o­neer­ing takes an­oth­er big step across the globe, plant­i­ng its biotech flag in Asia

Last year
Financing
Startups

Long­time can­cer R&D chief Pe­ter Lebowitz is tak­ing his fi­nal bows at J&J on­col­o­gy. Now what?

Last year
R&D

I'll be in Lon­don next week with the End­points crew and a great line­up of biotech ex­perts and in­sid­ers. Join us

Last year

Q3 snap­shot: The IPO mar­ket shows fresh signs of im­prove­ment, but the biotech crunch con­tin­ues to bite

Last year
1234 Next page Last page
A service from the Financial Times